A Phase 3 interventional study of LY2963016 and LANTUS® in Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Completed at 44 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-10-24.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 — 4 open to participants now, 6 under way, 1 of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 2.
Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, this one is the 48th largest by enrollment of the 175 interventional ones that give a count, is one of 8 that started in 2014, is one of 60 in phase 3, and was the 119th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →4 of the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:
Sanofi · Sites in China
Ages 18+
Loyola University · Sites in United States
Ages 18+ · Women only
Third Affiliated Hospital, Sun Yat-Sen University · Sites in China
Ages 30–65
Yanbing Li
Ages 18–70
By country, each count listing its studies:
Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
176 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 8 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 493 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 253 across the 175 interventional studies. Of the 161 that completed or were terminated, 56 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
122 of 176 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company: 10 open now, 21 under way, 11 of them phase 3. Of 211 finished, 155 (73%) have results posted.
Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one is the 56th largest by enrollment of the 232 interventional ones that give a count, is one of 8 that started in 2014, is one of 85 in phase 3, and was the 112th registered.
Eli Lilly and Company’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
1 of the studies testing Insulin Glargine in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07173712Yanbing LiRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 238 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate the safety and efficacy of the study drug known as LY2963016 as compared to LANTUS® in adults with type 2 diabetes mellitus who are on 2 or more oral antihyperglycemic medications (OAMs).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
As determined by the investigator, are capable and willing to do the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Insulin naive participants started on 10 units (U) LY2963016 given subcutaneously (SC) once a day (QD) for 24 weeks. Participants entering the study on LANTUS®, insulin detemir or neutral protamine hagedorn (NPH) QD will begin the study at their current dose SC. Participants will self titrate LY2963016 based on fasting blood glucose (FBG). Participants entering on insulin detemir or NPH twice a day will be started at 80% of the total daily dose SC. Participants will continue oral antihyperglycemic medication (OAM).
Drug: LY2963016 · Drug: Oral Antihyperglycemic Medication
Insulin naive participants started on 10 U LANTUS® given SC QD for 24 weeks. Participants entering the study on LANTUS®, insulin detemir or NPH QD will be started at the same dose SC. Participants entering on insulin detemir or NPH twice a day will be started at 80% of the total daily dose SC. Participants will self titrate LANTUS® based on FBG. Participants will continue OAM.
Drug: LANTUS® · Drug: Oral Antihyperglycemic Medication
Change From Baseline to 24 Weeks in Hemoglobin A1c (HbA1c)
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with baseline of response, treatment (LY2963016, LANTUS), pooled country, basal insulin at entry (yes/no), sulfonylurea (SU) use (yes/no), visit, treatment and visit\*treatment in the model.
Time frame: Baseline, 24 weeks
Percentage of Participants With HbA1c <7% and ≤6.5%
Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time.
Time frame: Endpoint [up to 24 weeks]
Change From Baseline in 7-point Self-Monitored Blood Glucose (SMBG) Values
Seven-point SMBG are completed at the following timepoints: Before Morning Meal, 2 Hours After Morning Meal, Before Mid-Day Meal, 2 Hours After Mid-Day Meal, Before Evening Meal, Bed Time and 03:00 AM hours. Least Squares (LS) means was determined by mixed model repeated measures (MMRM) methodology with baseline HbA1c, country, sulfonylurea use, basal insulin status at study entry, visit, treatment and visit\*treatment in the model.
Time frame: Baseline, Week 24
Intra-Participant Variability in Fasting Blood Glucose (FBG)
Fasting blood glucose (FBG) is a test to determine how much glucose (sugar) is in a blood sample after an overnight fast. Intra-Participant FBG variability was calculated based on the standard deviation (SD) of the morning pre-meal BG value. Least Squares (LS) means was determined by mixed model repeated measures (MMRM) methodology with baseline HbA1c, country, sulfonylurea use, basal insulin status at study entry, visit, treatment and visit\*treatment in the model.
Time frame: Week 24
Basal Insulin Dose Units Per Day
Units of Basal Insulin dose taken per day (U/day). Least Squares (LS) means was determined by mixed model repeated measures (MMRM) methodology with baseline of response, baseline HbA1c, country, sulfonylurea use, basal insulin status at study entry, visit, treatment and visit\*treatment in the model.
Time frame: Week 24
Basal Insulin Dose Per Body Weight (U/kg/Day)
Basal Insulin dose in units (U) per body weight in kilograms (kg) per day. Least Squares (LS) means was determined by mixed model repeated measures (MMRM) methodology with baseline of response, baseline HbA1c, country, sulfonylurea use, basal insulin status at study entry, visit, treatment and visit\*treatment in the model.
Time frame: Week 24
Change From Baseline to 24 Weeks in Body Weight
Change from baseline in body weight. Least Squares (LS) means was determined by mixed model repeated measures (MMRM) methodology with baseline of response, baseline HbA1c, country, sulfonylurea use, basal insulin status at study entry, visit, treatment and visit\*treatment in the model.
Time frame: Baseline, 24 Weeks
Insulin Treatment Satisfaction Questionnaire (ITSQ) Score
ITSQ is a validated instrument containing 22 items that assess treatment satisfaction for participants with diabetes and on insulin. Items divided into 5 domains of satisfaction: Inconvenience of Regimen \[(IR) 5 items: domain scores range (DSR) 5-35\], Lifestyle Flexibility \[(LF) 3 items: DSR 3-21\], Glycemic Control \[(GC) 3 items: DSR 3-21\], Hypoglycemic Control \[(HC) 5 items: DSR 5-35\], Insulin Delivery Device \[(IDD) 6 items: DSR 6-42\]. All items measured on a 7-point scale: 1 (no bother at all) to 7 (a tremendous bother), with lower scores reflecting better outcomes. ITSQ Total Overall Raw Scores range from 22-154. Both raw domain and overall scores are transformed on a scale of 0-100, where transformed score=100\*\[(7-mean raw score)/6\]. Higher scores indicate better treatment satisfaction. LS means was determined by MMRM with baseline of response, baseline HbA1c, country, sulfonylurea use, basal insulin status at study entry, visit, treatment and visit\*treatment in the model.
Time frame: Week 4 and Week 24
Percentage of Participants With Detectable Anti-Drug Antibodies to LY2963016 or LANTUS®
The percentage of participants with detected insulin antibodies were summarized as counts and percentages at baseline, at each visit, at the 24-week endpoint (LOCF), and overall for the 24-week treatment period.
Time frame: Endpoint [up to 24 weeks]
Rate of Hypoglycemic Events Adjusted Per 1 Year
The rate of hypoglycemic events were analyzed at baseline, titration, maintenance, and overall study periods and at endpoint using the Wilcoxon test. In addition, a negative binomial model was used as a sensitivity analysis. A hypoglycemic event is defined as any time a participant has a blood glucose (BG) level of ≤70 milligrams per deciliter (mg/dL) even if the event was not associated with signs, symptoms, or treatment consistent with current guidelines (American Diabetes Association 2005). Nocturnal hypoglycemia is defined as any hypoglycemic event that occurs between bedtime and waking. Severe hypoglycemia is defined as a hypoglycemic event requiring assistance of another person to actively administer carbohydrates, glucagons, or other resuscitative actions. Severe Hypoglycemic events may or may not have a reported BG ≤70 mg/dL. These events may be associated with sufficient neuroglycopenia to induce seizure or coma.
Time frame: Baseline through Endpoint [up to 24 weeks]
Percentage of Participants With Hypoglycemic Events
The percentage of participants (with at least 1 hypoglycemic event (total, severe, nocturnal, and others) or incidence during the study was analyzed using Fisher's exact test. A hypoglycemic event is defined as any time a participant has a blood glucose (BG) level of ≤70 milligrams per deciliter (mg/dL) even if the event was not associated with signs, symptoms, or treatment consistent with current guidelines (American Diabetes Association 2005). Nocturnal hypoglycemia is defined as any hypoglycemic event that occurs between bedtime and waking. Severe hypoglycemia is defined as a hypoglycemic event requiring assistance of another person to actively administer carbohydrates, glucagons, or other resuscitative actions. Severe Hypoglycemic events may or may not have a reported BG ≤70 mg/dL. These events may be associated with sufficient neuroglycopenia to induce seizure or coma.
Time frame: Endpoint [up to 24 weeks]
| Milestone | LY2963016 | LANTUS® |
|---|---|---|
| Started | 249 | 244 |
| Received at least 1 dose of study drug | 249 | 244 |
| Completed | 230 | 225 |
| Not completed | 19 | 19 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 1 |
| Withdrew: Lost to follow-up | 2 | 4 |
| Withdrew: Physician decision | 3 | 4 |
| Withdrew: Withdrawal by subject | 13 | 7 |
| Withdrew: Protocol violation | 0 | 1 |
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with baseline of response, treatment (LY2963016, LANTUS), pooled country, basal insulin at entry (yes/no), sulfonylurea (SU) use (yes/no), visit, treatment and visit\*treatment in the model.
| Percentage of glycosylated hemoglobin | LY2963016 | LANTUS® |
|---|---|---|
| Change From Baseline to 24 Weeks in Hemoglobin A1c (HbA1c) | -1.25 ± 0.066 | -1.22 ± 0.067 |
Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time.
| Percentage of participants | LY2963016 | LANTUS® |
|---|---|---|
| HbA1c- at 24 week endpoint (LOCF) < 7.0% | 35.0 | 38.3 |
| HbA1c- at 24 week endpoint (LOCF) <= 6.5% | 20.8 | 18.8 |
Seven-point SMBG are completed at the following timepoints: Before Morning Meal, 2 Hours After Morning Meal, Before Mid-Day Meal, 2 Hours After Mid-Day Meal, Before Evening Meal, Bed Time and 03:00 AM hours. Least Squares (LS) means was determined by mixed model repeated measures (MMRM) methodology with baseline HbA1c, country, sulfonylurea use, basal insulin status at study entry, visit, treatment and visit\*treatment in the model.
| Millimoles per liter (mmol/L) | LY2963016 | LANTUS® |
|---|---|---|
| 24 week- Before Morning Meal | -2.37 ± 0.083 | -2.69 ± 0.083 |
| 24 week- 2 Hours After Morning Meal | -2.78 ± 0.161 | -3.00 ± 0.160 |
| 24 week-Before Mid-Day Meal | -2.14 ± 0.135 | -2.20 ± 0.132 |
| 24 weeks- 2 Hours After Mid-Day Meal | -2.26 ± 0.158 | -2.42 ± 0.156 |
| 24 weeks-Before Evening Meal | -1.84 ± 0.156 | -2.25 ± 0.154 |
| 24 weeks- Bed Time | -2.14 ± 0.157 | -2.40 ± 0.156 |
| 24 weeks- 3:00 AM hrs | -2.09 ± 0.124 | -2.09 ± 0.122 |
Fasting blood glucose (FBG) is a test to determine how much glucose (sugar) is in a blood sample after an overnight fast. Intra-Participant FBG variability was calculated based on the standard deviation (SD) of the morning pre-meal BG value. Least Squares (LS) means was determined by mixed model repeated measures (MMRM) methodology with baseline HbA1c, country, sulfonylurea use, basal insulin status at study entry, visit, treatment and visit\*treatment in the model.
| mmol/L | LY2963016 | LANTUS® |
|---|---|---|
| Intra-Participant Variability in Fasting Blood Glucose (FBG) | 0.81 ± 0.049 | 0.79 ± 0.049 |
Units of Basal Insulin dose taken per day (U/day). Least Squares (LS) means was determined by mixed model repeated measures (MMRM) methodology with baseline of response, baseline HbA1c, country, sulfonylurea use, basal insulin status at study entry, visit, treatment and visit\*treatment in the model.
| Units per day (U/day) | LY2963016 | LANTUS® |
|---|---|---|
| Basal Insulin Dose Units Per Day | 49.8 ± 2.16 | 49.7 ± 2.17 |
Basal Insulin dose in units (U) per body weight in kilograms (kg) per day. Least Squares (LS) means was determined by mixed model repeated measures (MMRM) methodology with baseline of response, baseline HbA1c, country, sulfonylurea use, basal insulin status at study entry, visit, treatment and visit\*treatment in the model.
| units per kilogram per day (U/kg/day) | LY2963016 | LANTUS® |
|---|---|---|
| Basal Insulin Dose Per Body Weight (U/kg/Day) | 0.58 ± 0.024 | 0.61 ± 0.024 |
Change from baseline in body weight. Least Squares (LS) means was determined by mixed model repeated measures (MMRM) methodology with baseline of response, baseline HbA1c, country, sulfonylurea use, basal insulin status at study entry, visit, treatment and visit\*treatment in the model.
| Kilogram (kg) | LY2963016 | LANTUS® |
|---|---|---|
| Change From Baseline to 24 Weeks in Body Weight | 2.3 ± 0.28 | 1.7 ± 0.29 |
ITSQ is a validated instrument containing 22 items that assess treatment satisfaction for participants with diabetes and on insulin. Items divided into 5 domains of satisfaction: Inconvenience of Regimen \[(IR) 5 items: domain scores range (DSR) 5-35\], Lifestyle Flexibility \[(LF) 3 items: DSR 3-21\], Glycemic Control \[(GC) 3 items: DSR 3-21\], Hypoglycemic Control \[(HC) 5 items: DSR 5-35\], Insulin Delivery Device \[(IDD) 6 items: DSR 6-42\]. All items measured on a 7-point scale: 1 (no bother at all) to 7 (a tremendous bother), with lower scores reflecting better outcomes. ITSQ Total Overall Raw Scores range from 22-154. Both raw domain and overall scores are transformed on a scale of 0-100, where transformed score=100\*\[(7-mean raw score)/6\]. Higher scores indicate better treatment satisfaction. LS means was determined by MMRM with baseline of response, baseline HbA1c, country, sulfonylurea use, basal insulin status at study entry, visit, treatment and visit\*treatment in the model.
| units on a scale | LY2963016 | LANTUS® |
|---|---|---|
| IR-Week 4 | 85.79 ± 1.32 | 84.92 ± 1.33 |
| IR-Week 24 | 84.75 ± 1.26 | 84.91 ± 1.28 |
| LF-Week 4 | 71.43 ± 1.87 | 69.11 ± 1.89 |
| LF-Week 24 | 72.44 ± 1.77 | 70.87 ± 1.80 |
| HC-Week 4 | 77.82 ± 1.50 | 76.98 ± 1.52 |
| HC-Week 24 | 76.18 ± 1.46 | 76.52 ± 1.48 |
| GC-Week 4 | 79.24 ± 1.45 | 78.87 ± 1.46 |
| GC-Week 24 | 82.14 ± 1.36 | 81.30 ± 1.38 |
| IDD-Week 4 | 82.21 ± 1.23 | 82.37 ± 1.25 |
| IDD-Week 24 | 82.12 ± 1.29 | 82.01 ± 1.31 |
| ITSQ Overall Total-Week 4 | 80.15 ± 1.12 | 79.40 ± 1.13 |
| ITSQ Overall Total-Week 24 | 80.01 ± 1.13 | 79.76 ± 1.14 |
The percentage of participants with detected insulin antibodies were summarized as counts and percentages at baseline, at each visit, at the 24-week endpoint (LOCF), and overall for the 24-week treatment period.
| Percentage of participants | LY2963016 | LANTUS® |
|---|---|---|
| Percentage of Participants With Detectable Anti-Drug Antibodies to LY2963016 or LANTUS® | 14.5 | 17.2 |
The rate of hypoglycemic events were analyzed at baseline, titration, maintenance, and overall study periods and at endpoint using the Wilcoxon test. In addition, a negative binomial model was used as a sensitivity analysis. A hypoglycemic event is defined as any time a participant has a blood glucose (BG) level of ≤70 milligrams per deciliter (mg/dL) even if the event was not associated with signs, symptoms, or treatment consistent with current guidelines (American Diabetes Association 2005). Nocturnal hypoglycemia is defined as any hypoglycemic event that occurs between bedtime and waking. Severe hypoglycemia is defined as a hypoglycemic event requiring assistance of another person to actively administer carbohydrates, glucagons, or other resuscitative actions. Severe Hypoglycemic events may or may not have a reported BG ≤70 mg/dL. These events may be associated with sufficient neuroglycopenia to induce seizure or coma.
| Hypoglycemic events per 1 year | LY2963016 | LANTUS® |
|---|---|---|
| Total Hypoglycemia with BG ≤70 mg/dL | 16.95 ± 23.444 | 23.37 ± 35.809 |
| Severe Hypoglycemia | 0.00 ± 0.00 | 0.00 ± 0.02 |
| Nocturnal Hypoglycemia with BG ≤70 mg/dL | 6.64 ± 11.650 | 7.94 ± 17.882 |
The percentage of participants (with at least 1 hypoglycemic event (total, severe, nocturnal, and others) or incidence during the study was analyzed using Fisher's exact test. A hypoglycemic event is defined as any time a participant has a blood glucose (BG) level of ≤70 milligrams per deciliter (mg/dL) even if the event was not associated with signs, symptoms, or treatment consistent with current guidelines (American Diabetes Association 2005). Nocturnal hypoglycemia is defined as any hypoglycemic event that occurs between bedtime and waking. Severe hypoglycemia is defined as a hypoglycemic event requiring assistance of another person to actively administer carbohydrates, glucagons, or other resuscitative actions. Severe Hypoglycemic events may or may not have a reported BG ≤70 mg/dL. These events may be associated with sufficient neuroglycopenia to induce seizure or coma.
| Percentage of participants | LY2963016 | LANTUS® |
|---|---|---|
| Total hypoglycemia with BG ≤70 mg/dL | 68.7 | 69.1 |
| Severe hypoglycemia | 0 | 0.8 |
| Nocturnal hypoglycemia with BG ≤70 mg/dL | 49.6 | 46.1 |
| Non-nocturnal hypoglycemia with BG ≤70 mg/dL | 59.4 | 63.0 |
Collected over Up to 28 weeks. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LY2963016 | — | 10/249 (4%) | 75/249 (30.1%) |
| LANTUS® | — | 12/244 (4.9%) | 87/244 (35.7%) |
| Event | LY2963016 | LANTUS® |
|---|---|---|
| PneumoniaInfections and infestations | 0/249 | 2/244 |
| HypoglycaemiaMetabolism and nutrition disorders | 1/249 | 2/244 |
| Acute myocardial infarctionCardiac disorders | 0/249 | 1/244 |
| Cardiogenic shockCardiac disorders | 0/249 | 1/244 |
| Myocardial infarctionCardiac disorders | 0/249 | 1/244 |
| Supraventricular tachycardiaCardiac disorders | 0/249 | 1/244 |
| Macular holeEye disorders | 0/249 | 1/244 |
| BronchitisInfections and infestations | 0/249 | 1/244 |
| DiverticulitisInfections and infestations | 0/249 | 1/244 |
| Head injuryInjury, poisoning and procedural complications | 0/249 | 1/244 |
| Event | LY2963016 | LANTUS® |
|---|---|---|
| NasopharyngitisInfections and infestations | 18/249 | 24/244 |
| Upper respiratory tract infectionInfections and infestations | 10/249 | 9/244 |
| Weight increasedInvestigations | 8/249 | 4/244 |
| Injection site painGeneral disorders | 2/249 | 7/244 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/249 | 7/244 |
| Abnormal weight gainMetabolism and nutrition disorders | 7/249 | 5/244 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 3/249 | 5/244 |
| HeadacheNervous system disorders | 4/249 | 5/244 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 1/249 | 5/244 |
| VomitingGastrointestinal disorders | 2/249 | 4/244 |
All randomized participants who received at least 1 dose of study drug.
| Age, Continuous(years) | LY2963016 | LANTUS® | Total |
|---|---|---|---|
| Mean | 57.82 ± 8.83 | 56.98 ± 9.86 | 57.40 ± 9.35 |
| Sex: Female, Male(Participants) | LY2963016 | LANTUS® | Total |
|---|---|---|---|
| Female | 118 | 118 | 236 |
| Male | 131 | 126 | 257 |
| Race (NIH/OMB)(Participants) | LY2963016 | LANTUS® | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 116 | 118 | 234 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 15 | 15 | 30 |
| White | 115 | 110 | 225 |
| More than one race | 2 | 1 | 3 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | LY2963016 | LANTUS® | Total |
|---|---|---|---|
| South Korea | 47 | 45 | 92 |
| Puerto Rico | 29 | 33 | 62 |
| Turkey | 15 | 10 | 25 |
| United States | 60 | 57 | 117 |
| Taiwan | 20 | 22 | 42 |
| India | 49 | 51 | 100 |
| Russia | 29 | 26 | 55 |
| Baseline Hemoglobin A1c (HbA1c)(Percentage of glycosylated hemoglobin) | LY2963016 | LANTUS® | Total |
|---|---|---|---|
| Mean | 8.66 ± 1.09 | 8.56 ± 1.02 | 8.61 ± 1.06 |
| Sulfonylurea Group(Participants) | LY2963016 | LANTUS® | Total |
|---|---|---|---|
| Yes, did use sulfonylurea | 207 | 207 | 414 |
| No, did not use sulfonylurea | 42 | 37 | 79 |
| Duration of Diabetes(years) | LY2963016 | LANTUS® | Total |
|---|---|---|---|
| Mean | 11.59 ± 6.34 | 12.26 ± 6.45 | 11.92 ± 6.40 |
| Time of basal insulin injection(Participants) | LY2963016 | LANTUS® | Total |
|---|---|---|---|
| Daytime | 99 | 96 | 195 |
| Evening/Bedtime | 150 | 148 | 298 |
Plan to share: Yes — Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com. This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.
The record gives a start of Dec 2014, a primary completion of Jul 2016 and a completion of Jul 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2017, 1 year 3 months after primary completion. A results delay was requested in Dec 2016.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin Glargine